XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.1

Business Segments (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Revenue and net income for the Company’s biotherapeutics segment are shown below:

			Three Months Ended March 31,
			2025						2024
Revenue from research and development collaborations			$	27,110					$	10,030
Segment expenses:
Zanidatamab			1,403						3,388
ZW171			2,226						2,298
ZW191			1,706						2,726
ZW220			2,199						3,367
ZW251			3,951						607
Zanidatamab zovodotin			349						2,649
Expense for other preclinical and research programs			5,726						2,810
Salaries and benefits			13,840						13,348
Other research and development expense			4,848						3,741
Other general and administrative expense			7,475						8,283
Total segment expenses			43,723						43,217
Segment loss			(16,613)						(33,187)
Reconciling items:
Depreciation and amortization			(2,598)						(1,763)
Stock-based compensation expense			(6,402)						(3,552)
Change in contingent consideration			—						700
Interest income			3,424						5,920
Other income, net			49						304
Income tax expense			(496)						(75)
Net loss			$	(22,636)					$	(31,653)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration